Liver transplantation for hepatocellular carcinoma: Five steps to prevent recurrence

American Journal of Transplantation

Volumn 11, Issue 10, 2011, Pages 2031-2035

  Toso, C ^a   Mentha, G ^a   Majno, P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Cell; circulating; hepatocellular carcinoma; ischemia reperfusion; liver; transplantation

Indexed keywords

ALPHA FETOPROTEIN; DOXORUBICIN; LICARTIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; RAPAMYCIN; SORAFENIB; THYMIDINE KINASE; UNCLASSIFIED DRUG;

CANCER MORTALITY; CANCER RECURRENCE; DISEASE MARKER; ENGRAFTMENT; HUMAN; ISCHEMIA; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NONHUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; RISK FACTOR; TUMOR CELL; UNSPECIFIED SIDE EFFECT;

CARCINOMA, HEPATOCELLULAR; HEALTH SERVICES ACCESSIBILITY; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL;

EID: 81155161826     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03689.x     Document Type: Review

References (41)

1. Mazzaferro V, Llovet JM, Miceli R, et al,. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
2. Toso C, Kneteman NM, James Shapiro AM, Bigam DL,. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int 2009; 22: 869-875.
3. Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, Makuuchi M,. Alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: A prospective study. Hepatology 2002; 35: 853-860. (Pubitemid 34258379)
4. Marubashi S, Dono K, Nagano H, et al,. Detection of AFP mRNA-expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation. Transpl Int 2007; 20: 576-582. (Pubitemid 46872747)
5. Lemoine A, Le BT, Salvucci M, et al,. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery. Ann Surg 1997; 226: 43-50. (Pubitemid 27468902)
6. Cillo U, Vitale A, Bassanello M, et al,. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2005; 239: 150-159.
7. Lee JW, Paeng JC, Kang KW, et al,. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009; 50: 682-687.
8. DuBay D, Sandroussi C, Sandhu L, et al,. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011; 253: 166-172.
9. Toso C, Meeberg GA, Bigam DL, et al,. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects. Transplantation 2007; 83: 1162-1168. (Pubitemid 46743675)
10. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM,. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832-838.
11. Pomfret EA, Washburn K, Wald C, et al,. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16: 262-278.
12. Llovet JM, Bruix J,. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327.
13. Toffanin S, Hoshida Y, Lachenmayer A, et al,. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011; 140: 1618-1628.
14. Yao FY, Kerlan RK, Jr,., Hirose R, et al,. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: An intention-to-treat analysis. Hepatology 2008; 48: 819-827.
15. Merani S, Majno P, Kneteman NM, et al,. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011.
16. Ravaioli M, Grazi GL, Ercolani G, et al,. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 2004; 78: 1780-1786. (Pubitemid 40041645)
17. Majno PE, Adam R, Bismuth H, et al,. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688-701.
18. Millonig G, Graziadei IW, Freund MC, et al,. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-279. (Pubitemid 46351654)
19. Edwards E, Harper A, Freeman R,. The effect of pre-transplant ablation therapy on post-transplant outcome in liver recipients with hepatocellular carcinoma. Am J Transplant 2008; 8: 267.
20. Toso C, Mentha G, Kneteman NM, Majno P,. The place of downstaging for hepatocellular carcinoma. J Hepatol 2010; 52: 930-936.
21. Liu CL, Fan ST, Cheung ST, Lo CM, Ng IO, Wong J,. Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: A prospective randomized controlled study. Ann Surg 2006; 244: 194-203. (Pubitemid 44305533)
22. Wu TJ, Wang F, Lin YS, Chan KM, Yu MC, Lee WC,. Right hepatectomy by the anterior method with liver hanging versus conventional approach for large hepatocellular carcinomas. Br J Surg 2010; 97: 1070-1078.
23. van der Bilt JD, Kranenburg O, Nijkamp MW, et al,. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 2005; 42: 165-175. (Pubitemid 40911324)
24. van der Bilt JD, Kranenburg O, Borren A, van HR, Borel R, I. Ageing and hepatic steatosis exacerbate ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. Ann Surg Oncol 2008; 15: 1392-1398.
25. Man K, Lo CM, Xiao JW, et al,. The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. Ann Surg 2008; 247: 1049-1057. (Pubitemid 351770427)
26. Man K, Shih KC, Ng KT, et al,. Molecular signature linked to acute phase injury and tumor invasiveness in small-for-size liver grafts. Ann Surg 2010; 251: 1154-1161.
27. Fisher RA, Kulik LM, Freise CE, et al,. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007; 7: 1601-1608. (Pubitemid 46776250)
28. Vakili K, Pomposelli JJ, Cheah YL, et al,. Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. Liver Transpl 2009; 15: 1861-1866.
29. Bhangui P, Vibert E, Majno P, et al,. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: Living versus deceased donor transplantation. Hepatology 2011; 53: 1570-1579.
30. Pokorny H, Gnant M, Rasoul-Rockenschaub S, et al,. Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant 2005; 5: 788-794. (Pubitemid 40461289)
31. Xu J, Shen ZY, Chen XG, et al,. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007; 45: 269-276. (Pubitemid 46374583)
32. Li N, Zhou J, Weng D, et al,. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2007; 13: 5847-5854. (Pubitemid 47583910)
33. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM,. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-1243.
34. Llovet JM, Ricci S, Mazzaferro V, et al,. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
35. Wang GB, Zhou XY, Wang XQ,. Relationship between serum heparanase and microscopic venous invasion in patients with hepatocellular carcinoma. Am J Clin Pathol 2010; 134: 242-248.
36. Liu CJ, Lee PH, Lin DY, et al,. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. J Hepatol 2009; 50: 958-968.
37. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al,. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients. World J Gastroenterol 2006; 12: 7319-7325. (Pubitemid 44911839)
38. Stehling O, Grau V, Steiniger B,. Monocyte cytotoxicity during acute kidney graft rejection in rats. Int Immunol 2004; 16: 101-110. (Pubitemid 38054631)
39. Chang CJ, Chen YH, Huang KW, et al,. Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology 2007; 45: 746-754.
40. Ohira M, Ohdan H, Mitsuta H, et al,. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation 2006; 82: 1712-1719. (Pubitemid 46035657)
41. Eissens DN, Van Der MA, Van CB, Preijers FW, Joosten I,. Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotype. Am J Transplant 2010; 10: 1981-1990.